Tag
Cryptogenic steatotic liver disease (SLD), representing a lean phenotype without classic cardiometabolic risk factors, is associated with adverse liver profiles and higher liver-related mortality, highlighting an underrecognized high-risk s
Cryptogenic steatotic liver disease (SLD) is a form of fatty liver disease found in lean individuals without diabetes or other metabolic risk factors, associated with significant liver injury and increased mortality risk.
Unclassified pulmonary hypertension often reflects early-stage HFpEF linked to left heart and metabolic dysfunction, identifiable via dynamic right heart catheterization and metabolomics.
In a 32-center international cohort, cardiometabolic risk factors were common in alcohol-associated hepatitis but did not independently increase 180-day mortality after adjustment for liver disease severity and competing transplant risk.
Recent clinical evidence reveals that soluble amyloid-beta oligomers, rather than traditional plaques, drive glucose dysregulation and depression in early Alzheimer’s disease. Crucially, these associations are modulated by tau pathology, su
This review synthesizes findings from the MAESTRO-NASH trial, highlighting that Resmetirom’s efficacy is maintained alongside GLP-1 RAs and SGLT2 inhibitors, while being significantly enhanced by concurrent weight loss.
Metabolic dysfunction and MASLD elevate hepatocellular carcinoma risk in chronic hepatitis B patients. The PAGE-B score effectively stratifies this risk, especially in non-cirrhotic patients, while cirrhotic patients still require careful m
Waist circumference is a superior predictor of metabolic liver diseases, outperforming BMI and other body metrics in assessing MASLD, MASH, and liver stiffness risks.
